Biocompatibility and degradation of poly(DL-lactic-co-glycolic acid)/calcium phosphate cement composites

被引:97
作者
Ruhé, PQ
Hedberg, EL
Padron, NT
Spauwen, PHM
Jansen, JA
Mikos, AG
机构
[1] Rice Univ, Dept Bioengn, Houston, TX 77251 USA
[2] Radboud Univ Nijmegen, Med Ctr, Dept Biomat, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Plast & Reconstruct Surg, NL-6500 HB Nijmegen, Netherlands
关键词
biocompatibility; bone engineering; calcium phosphate; PLGA microparticles; porosity;
D O I
10.1002/jbm.a.30341
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Injectable calcium phosphate (Ca-P) cement materials exhibit favorable osteocompatible behavior but are resorbed slowly because of a lack of a bone ingrowthenabling macroporosity. In this study, poly((DL)-lactic-co-glycolic acid) (PLGA) microparticles (average size 66 +/- 25 mu m) were incorporated into Ca-P cement to obtain a macroporous Ca-P cement scaffold after PLGA hydrolysis in vivo. Preset PLGA/Ca-P cement composite discs of various weight ratios (0/100, 15/85, 30/70, and 50/50) were implanted subcutaneously and in cranial defects in rats for 12 weeks. Histological analysis revealed that all macropores in the PLGA-containing composites (average pore size 73 +/- 27 mu m) were filled with fibrous tissue and blood vessels (subcutaneous implants) and/or bone (cranial implants). Histologically, bone formation appeared most abundant and most consistent in the 30 / 70 PLGA / Ca-P cement composites. His- tomorphometrical evaluation revealed a significant increase in defect fill in the 15/85 and 30/70 PLGA/Ca-P cement composites. Finally, subcutaneous and cranial 50/50 PLGA/ Ca-P cement composites had degraded to a large extent, without adequate replacement by bone in the cranial implants. Therefore, we conclude that PLGA/Ca-P cement composites enable tissue ingrowth and show excellent osteocompatibility in weight ratios of 15/85 and 30/70 PLGA/ Ca-P cement. In this model, 30/70 PLGA/Ca-P cement composites showed the most favorable biological response. (c) 2005 Wiley Periodicals, Inc.
引用
收藏
页码:533 / 544
页数:12
相关论文
共 32 条
[1]   OSTEOCLASTIC RESORPTION OF CA-P BIOMATERIALS IMPLANTED IN RABBIT BONE [J].
BASLE, MF ;
CHAPPARD, D ;
GRIZON, F ;
FILMON, R ;
DELECRIN, J ;
DACULSI, G ;
REBEL, A .
CALCIFIED TISSUE INTERNATIONAL, 1993, 53 (05) :348-356
[2]   In vivo evaluation of gene therapy vectors in ex vivo-derived marrow stromal cells for bone regeneration in a rat critical-size calvarial defect model [J].
Blum, JS ;
Barry, MA ;
Mikos, AG ;
Jansen, JA .
HUMAN GENE THERAPY, 2003, 14 (18) :1689-1701
[3]  
Brown W.E., 1985, U.S. Patent, Patent No. [No. 4518430, 4518430]
[4]  
Bucholz RW, 2002, CLIN ORTHOP RELAT R, P44
[5]  
Chow L C, 2001, Monogr Oral Sci, V18, P148
[6]  
Cleek RL, 1997, J BIOMED MATER RES, V35, P525, DOI 10.1002/(SICI)1097-4636(19970615)35:4<525::AID-JBM12>3.0.CO
[7]  
2-A
[8]   Closure of critical sized defects with allogenic and alloplastic bone substitutes [J].
Clokie, CML ;
Moghadam, H ;
Jackson, MT ;
Sandor, GKB .
JOURNAL OF CRANIOFACIAL SURGERY, 2002, 13 (01) :111-121
[9]   In vivo bone response to porous calcium phosphate cement [J].
del Real, RP ;
Ooms, E ;
Wolke, JGC ;
Vallet-Regí, M ;
Jansen, JA .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2003, 65A (01) :30-36
[10]   A new method to produce macropores in calcium phosphate cements [J].
del Real, RP ;
Wolke, JGC ;
Vallet-Regí, M ;
Jansen, JA .
BIOMATERIALS, 2002, 23 (17) :3673-3680